Gubra A/S (GUBRA.CO) - Deep Dive Research Report

Prepared: 25 May 2026 | Most recent reporting period: Q1 2026 (trading statement, 12 May 2026)

1. What the Company Does

Gubra is a Danish biotech and preclinical contract research organisation (CRO) headquartered in Hørsholm, north of Copenhagen, that does two things commercially and one thing intellectually. Commercially, it sells preclinical research services (lab studies in obese rodents, peptide chemistry, histology, imaging) to almost every large pharma running an obesity or diabetes programme, and it discovers its own peptide drug candidates which it then licenses to big pharma in exchange for upfront cash, milestones and royalties. Intellectually, what holds the two halves together is a single deep capability: 17 years of accumulated know-how in the biology of metabolic disease, especially appetite, fat mass, lean mass and the gut-brain hormonal axis. That is the moat. The CRO sells access to it by the study; the biotech turns it into proprietary drugs.

The company was founded in 2008 in Denmark by two scientists, Jacob Jelsing and Niels Vrang. The two are still the largest shareholders by a wide margin (about 58% combined) and Vrang sits on the board today after stints as CEO (2010-2016), Chair (2016-2022) and CSO (2022-2024). The founding story matters because Gubra was originally a pure preclinical CRO. The "we discover our own drugs too" half was bootstrapped from CRO cash flow over many years, which is unusual in biotech. Most peptide drug discovery shops start with venture money and burn it; Gubra started with services revenue and reinvested it, which is why the company reached an IPO (April 2024 on Nasdaq Copenhagen at DKK 110/share) with a real product engine and a real services engine already running.

The technical core of the business is something called peptide-based drug discovery, and within that, the company has a proprietary platform called streaMLine. Peptides are short chains of amino acids that act as signalling molecules in the body. Most of the new obesity drugs everyone is talking about (semaglutide, tirzepatide, retatrutide) are peptides that mimic gut hormones. The challenge with designing a useful peptide drug is twofold: (1) you need to know which receptors to hit and in what combination to get the biological effect you want without intolerable side effects (a biology problem); (2) you need to chemically engineer a small molecule with the right binding affinity, the right pharmacokinetic profile (so it can be dosed weekly or less, not daily), and the right manufacturability (an organic chemistry problem). Gubra runs both ends in-house, using its own in vivo rodent obesity models to validate hits before they ever go anywhere near a human. That tight feedback loop between discovery chemistry and validated biology is what the company sells.

A concrete example: in March 2025, AbbVie paid Gubra $350 million in cash upfront plus up to $1.875 billion in milestones plus tiered royalties for the global rights to one drug, ABBV-295 (originally GUB014295, branded GUBamy). It is a once-weekly long-acting amylin analog for obesity. Gubra discovered it, did all the preclinical work and ran the Phase 1 single-ascending dose study. Once Phase 1 multiple-ascending dose data showed patients losing 7.75-9.79% of body weight in roughly three months at the top doses with mild gastrointestinal side effects (per the AbbVie partnership announcement), AbbVie took over development and pays Gubra at every clinical and regulatory milestone hit, and a royalty on sales if approved. That single deal made Gubra cash-flow positive for years and let it distribute DKK 1 billion to shareholders as a special dividend in July 2025. Everything else in the report ties back to whether Gubra can do this again.

2. Business Segments

Starting in 2026, Gubra reports through three segments: Biotech, CRO, and a new Ventures unit. In 2025 reporting, Biotech and CRO were the only two and were called "Discovery & Partnerships" and "CRO". The 2025 revenue mix was roughly 92% Biotech / 8% CRO, but that mix is wildly distorted by the AbbVie upfront payment recognised in H1 2025. In a normalised year without a huge upfront, the mix is closer to 60-70% CRO and 30-40% Biotech (milestones, residual royalties, research-stage payments).

Biotech (~92% of 2025 revenue, distorted by AbbVie)

What it does: discovers peptide-based drug candidates for metabolic and cardiometabolic diseases (obesity, diabetes, MASH, hypoparathyroidism, cardio-renal indications) and out-licenses them to large pharma partners. Revenue comes in three forms: upfront cash on signing a deal, milestone payments as the partner advances the asset through clinical trials and regulatory approvals, and royalties on commercial sales. Gubra has no commercial product of its own and no intention of building one. It is a discovery shop.

The core capability is the integrated peptide platform. Designing a peptide that hits one receptor selectively, hits two receptors in the right ratio, or hits three receptors with the right pharmacokinetics for once-weekly dosing is a multi-year apprenticeship. Add to that the in vivo validation in proprietary obesity rodent models that the CRO half has been refining for 15+ years, and you have a discovery engine that can credibly compete head-to-head with Novo Nordisk and Eli Lilly. The five-year proof point is the three "potential multibillion" obesity drugs the company has in or about to enter clinical trials: ABBV-295 (out-licensed to AbbVie, Phase 2 Q3 2026), the GLP-1/GIP/Y2 triple agonist (out-licensed to Boehringer Ingelheim, Phase 2 mid-2026), and GUB-UCN2 (wholly owned, Phase 1/2a started 2026).

This segment exists as a separate unit because it has entirely different economics from the CRO. It produces lumpy, very high-margin revenue (90% adjusted EBIT margin in 2025), eats large internal R&D costs in years between deals, and is fundamentally a bet-the-shop business where one good deal can pay for a decade of discovery work. Management's stated strategy is to keep three to five assets in active discovery at any time, partner the ones with global commercial scale to big pharma, and keep one or two flagship assets internal until early clinical proof-of-concept to capture more value (which is exactly the GUB-UCN2 playbook).

Competitive position: there are very few peer companies that combine proprietary peptide discovery with deep obesity biology at this stage. The closest analogues are private biotechs working amylin (Zealand Pharma, also Danish, is the most-cited peer for amylin; Boehringer Ingelheim and Novo Nordisk are doing it in-house), but Gubra differentiates by being multi-mechanism (amylin, triple agonist, UCN2) and by its CRO-derived validation infrastructure. Within Gubra the segment is unambiguously the upside engine and the reason the stock exists in its current form.

CRO (~8% of 2025 revenue, normalised ~60-70%)

What it does: sells preclinical research studies to pharma and biotech customers who want to test their own drug candidates in rodent disease models. The focus is on metabolic and cardio-renal indications: diet-induced obesity (DIO) mice and rats, diabetic models, MASH (metabolic dysfunction-associated steatohepatitis), chronic kidney disease, fibrosis, and gastrointestinal disorders. Services span peptide chemistry, in vivo pharmacology, ex vivo tissue assays, molecular pharmacology, histology, imaging (including whole-brain imaging at single-cell resolution), stereology, next-generation sequencing and bioinformatics.

The core capability is the depth and credentialled rigour of the obesity model platform. A pharma customer outsources a study to Gubra not because it cannot run a DIO mouse study itself (most can), but because Gubra's models have been used in hundreds of published studies and Gubra's data packages are accepted by partners as decision-quality. The capability also includes the integrated multi-omics readouts: a customer can get not just a body weight curve but also adipose, muscle and liver histology, brain imaging showing which neurons are activated, and RNA sequencing showing which gene programmes are turned on. Few CROs can do that integrated package.

This segment exists as a separate unit because it has CRO economics (recurring, project-based, lower margin, scales with headcount) rather than biotech economics (lumpy, high margin, scales with deal flow). It is also what physically funds the building, the wet labs, the rodent colonies and the staff that the biotech half uses for proprietary discovery. The two halves share the same scientists, the same instruments and the same animal facility.

Competitive position: Gubra competes against the in vivo metabolic disease divisions of large global CROs (Charles River Laboratories, Crown Bioscience, which Charles River partnered with on the ZDSD diabetes rat) and against specialist peers (Physiogenex in France, PsychoGenics in the US for CNS but with some metabolic crossover, Nordic Bioscience Clinical Development). Gubra wins on metabolic-disease depth and scientific reputation, loses on geographic reach (it is a single-site Danish operation) and on scale. As of Q1 2026 the segment was visibly hurting from the macro environment for small/mid-cap biotech customers: longer decision cycles, smaller study sizes, intensified competition on commodity studies. 2026 CRO revenue guidance was cut at Q1 from 5-15% growth to 0-10% growth.

Within Gubra, this segment is treated as the strategic foundation rather than the growth bet. Management's articulated 10% long-term annual growth ambition for CRO is real but second-priority to biotech execution.

Ventures (new in 2026, no revenue yet)

What it does: a newly-created internal unit, announced with the 2025 annual report, designed to source assets externally (in-license or acquire promising preclinical candidates) and develop them inside Gubra using the same discovery and CRO infrastructure. First venture creation is expected H2 2026. The head is Zoë Johnson.

The core capability is leveraging Gubra's scientific judgement and operational infrastructure to find and de-risk assets that other people own. The thesis is that Gubra's discovery scientists see hundreds of academic papers, biotech pitches and CRO requests for proposals every year and can spot mispriced opportunities that a purely internal discovery effort would miss. Ventures gives them a structured way to act on those signals.

This segment exists as a separate unit because management wants to ringfence the capital allocation discipline. Without ringfencing, "let's also try this acquired asset" tends to consume internal resources from the discovery pipeline. The hope is also to bring outside co-investors into ventures so the cash burn is shared.

Competitive position: too early to assess. The model is not unique; specialty biotech venture vehicles like Roivant and Bridgebio have done variations. Differentiator if it works: tight integration with a working CRO that can run preclinical packages at marginal cost. Whether Ventures becomes the third leg of the stool or quietly winds down depends on execution over the next two to three years.

3. Products and Business Detail

The "product catalogue" splits in two: drug candidates (Biotech) and study services (CRO).

Drug candidates

ABBV-295 (formerly GUB014295, code-named GUBamy) is the headline asset. It is a long-acting amylin analog. Amylin is a hormone co-secreted with insulin from pancreatic beta cells that suppresses appetite and slows gastric emptying. A synthetic version, pramlintide, has been used for years in diabetes; the new generation of long-acting amylin analogs is the most credible "next big thing" after GLP-1 in obesity, because amylin appears to produce satiety with potentially less of the nausea, vomiting and lean-mass loss seen with GLP-1s. GUBamy is dosed once weekly subcutaneously. Phase 1 multiple-ascending-dose data showed mean weight loss of approximately 8-10% after 12 weeks at the higher doses with a "favourable tolerability profile". The asset was out-licensed to AbbVie in March 2025; AbbVie now runs all clinical development. Per the Q1 2026 call (12 May 2026), Phase 2 is expected to start Q3 2026.

Triple agonist (GLP-1/GIP/Y2) is Gubra's other late-stage out-licensed asset, partnered with Boehringer Ingelheim. It activates three different receptors (GLP-1 and GIP for the classic appetite/insulin effect, Y2 for an additional appetite-suppression mechanism). Phase 2 is expected to begin "by middle of the year" 2026 per the Q1 2026 call. The Boehringer relationship goes back to a 2017 agreement and was expanded with multiple obesity candidates in 2021. One earlier Boehringer candidate from the partnership, BI 1820237 (a long-acting NPY2 agonist), was discontinued, so there is precedent for partners walking away from individual assets.

GUB-UCN2 is the wholly-owned flagship asset. It is a long-acting urocortin-2 (UCN2) peptide that selectively activates the CRHR2 receptor. The biological angle is unusual and potentially differentiated: in mouse studies, GUB-UCN2 reduces fat mass while preserving or even increasing skeletal muscle mass, including when combined with a GLP-1. This matters because clinicians are increasingly worried that 20-45% of weight lost on current obesity drugs is lean tissue (muscle, bone, organs), which is medically undesirable, especially in older patients. Gubra positions UCN2 as either a standalone "healthy weight loss" therapy or as a muscle-sparing add-on to GLP-1s. The clinical trial application has been submitted; the Phase 1/2a is "very ambitious," enrolling approximately 188 participants over up to 16 weeks of treatment in selected cohorts, including both healthy volunteers and people with obesity, with and without comorbidities, both standalone and in combination with an incretin.

Camurus-partnered PTH analog for hypoparathyroidism: an in-licensed partnership where Gubra contributes its proprietary streaMLine-discovered parathyroid hormone analog peptides. This is the company's example of taking the platform beyond pure obesity.

Earlier-stage and undisclosed assets: Gubra also has earlier-stage research-stage collaborations and a 2019-vintage Bayer deal (up to $253m biobucks) on cardiovascular and kidney indications. The pipeline is not exhaustively disclosed because much of it is collaborative.

Study services (CRO)

The CRO catalogue is organised by disease area and by capability. Disease areas: obesity, diabetes, MASH, chronic kidney disease, fibrosis, gastrointestinal diseases, and a recently expanded women's health line. Capabilities: peptide chemistry (custom synthesis), in vivo pharmacology (the rodent dosing-and-readout studies that are the bread and butter), ex vivo assays (tissue-level readouts), molecular pharmacology (receptor-level mechanism studies), histology, imaging (including whole-brain imaging), stereology, RNA sequencing and bioinformatics.

The signature offering is the diet-induced obesity (DIO) model package: rodents made obese on a high-fat diet over weeks or months, dosed with a customer's compound, and then read out across a battery of endpoints including body composition, food intake, glucose tolerance, lipid panels, histology of adipose/muscle/liver, and increasingly brain imaging to see where in the brain the compound is acting. A customer typically buys a study package, not a single test.

Manufacturing and operations

Gubra is a single-site operation. Discovery labs, peptide chemistry, animal facility and corporate functions are all at the Hørsholm headquarters. The company does not manufacture commercial drug product. For its own drug candidates, manufacturing of clinical-trial material is contracted out to CDMOs; once a candidate is licensed to a pharma partner, the partner takes over all manufacturing. This is a capital-light model: most operating spend is people (PhD scientists, animal facility staff, chemists) and consumables.

Geographies and customer footprint

Operations are entirely in Denmark. Customers are global: large pharma headquarters across the US, Europe and Japan, plus the global small/mid-cap biotech ecosystem that does metabolic disease work. The US is the single most important customer geography for the CRO business and has been the source of most of the 2025-2026 weakness, with management calling out longer decision cycles among US smaller biotech customers as funding for that segment dried up. Management announced a 20% expansion of the US sales team at the Q1 2026 call (12 May 2026) to push harder into that market as funding conditions improve.

4. Customers

Gubra's customer base divides cleanly into two groups with very different buying behaviour.

The biotech segment has a tiny number of customers and the customer is always a large global pharmaceutical company. The named deals are with AbbVie (the $2.2bn ABBV-295 licence), Boehringer Ingelheim (multiple obesity candidates including the triple agonist), Bayer (cardio-renal, signed 2019), Sanofi (a research collaboration going back to 2012), and Camurus (a smaller specialty pharma partner on hypoparathyroidism). The buying decision is made by R&D leadership and ultimately the BD/licensing team at the pharma partner, typically following a multi-quarter scientific diligence process. The criteria are: is the biology compelling, is the asset differentiated from anything the pharma already has internally, does the preclinical package give confidence that the drug will work in humans, and is the IP defensible. Sales cycles are years from first contact to deal; the AbbVie deal followed years of relationship-building during which Gubra advanced GUBamy through preclinical and into early Phase 1. Switching costs do not really apply because each deal is for a specific asset; once signed, it is the pharma partner's to develop or walk away from. The reason these customers choose Gubra is essentially scientific reputation: Gubra has shown it can discover obesity peptides that work, and right now there is no obesity pipeline more wanted in pharma BD departments than amylin and muscle-sparing assets.

The CRO segment has a much larger customer roster, in the dozens, spanning every type of metabolic-disease drug developer from big pharma to seed-stage biotech. The buying decision is usually made by a Director or VP of preclinical research who needs a high-quality study run on an asset. The criteria are: does this CRO know my disease area, have they run this kind of study before, can they deliver a publication-grade data package on a defensible timeline, and what is the price. Sales cycles for a single study can be as short as weeks once a customer is qualified; bringing on a new customer takes longer. Switching costs are real but not enormous: once a customer has used Gubra for a study and accepted its data, the next study tends to come back to Gubra because the comparability of results across studies is itself valuable. But there is no contractual lock-in.

Concentration is the asymmetry between the two segments. Biotech revenue is concentrated in literally three or four deals at any time; ABBV-295 alone produced the vast majority of 2025 revenue. CRO revenue is much more diversified, spread across many studies and customers, though management has explicitly called out that 2025-2026 weakness has been driven by smaller US biotech customers stretching their procurement decisions or cancelling studies because their own funding has dried up.

Contract structures: biotech deals are typical upfront-plus-milestones-plus-royalties licence agreements, long-duration and structured around clinical decision points. CRO contracts are short, per-study, with payment on milestones (study initiation, interim readouts, final report). There is essentially no multi-year recurring revenue base on the CRO side; it is rebought year by year, study by study.

5. Competitive Landscape

The competitive landscape is genuinely different for the two halves of the business, so they need separate treatments.

Biotech (drug discovery)

The peer set is not the giant in-house obesity efforts at Novo Nordisk and Eli Lilly (those are the customers for the type of asset Gubra discovers, not competitors). The peer set is the small group of specialist peptide-discovery shops with credible obesity assets. The most-cited peer is Zealand Pharma, another Danish peptide-discovery company with a long-acting amylin analog (petrelintide) and an active deal-making strategy. Beyond Zealand, there are private biotechs and academic spin-outs working on multi-receptor obesity peptides, but most are earlier stage or less prolific. Within publicly observable pharma deals, MBX Biosciences, Viking Therapeutics, Structure Therapeutics and others have differentiated assets but are mostly developing them internally rather than out-licensing.

What Gubra wins on against this peer set: speed of pipeline replenishment (three Phase 1+ assets discovered in-house simultaneously is more than most peers can field), depth of in vivo biology validation before partnering (which materially de-risks Phase 1 attrition for partners), and the credibility of Niels Vrang and Jacob Jelsing as obesity scientists who have published widely. What Gubra loses on: it does not develop its own drugs through registration, so it captures less value per asset than a pure-play biotech that goes the full clinical distance.

Barriers to entry are substantial. You cannot stand up a Gubra-equivalent in three years. The combination of (a) peptide chemistry expertise, (b) deep obesity biology, (c) validated proprietary rodent models, and (d) the trust relationships with pharma BD teams that produce a $2.2bn licence takes a decade-plus to build. The current obesity gold rush makes capital cheap for anyone trying, but capital alone does not buy 17 years of accumulated know-how.

CRO (preclinical services)

Here the competitive set is the in vivo metabolic disease divisions of the big global CROs and a handful of specialists. Charles River Laboratories is the largest, with a global footprint, broad disease coverage including cardio-metabolic, and a ZDSD rat partnership with Crown Bioscience. Crown Bioscience (now part of JSR/Sumitomo) competes more on Asia-pacific reach and oncology, but does metabolic disease too. Other named specialists include Physiogenex (France, also metabolic-focused) and the metabolic divisions inside larger CROs like Labcorp and Eurofins. PsychoGenics is a closer comparator on the specialist model but is CNS-focused.

What Gubra wins on against the big CROs: depth of obesity-specific expertise, integrated multi-omics readouts, and scientific reputation in the niche. Big pharma metabolic researchers often want a Gubra study specifically. What Gubra loses on: it cannot offer the bundled services (toxicology, bioanalysis, GLP-compliant facilities for regulatory studies) that a Charles River can. Customers often use Gubra for the scientifically interesting in vivo work and a big CRO for the regulatory toxicology around it.

Barriers to entry on the CRO side are real but lower than on the Biotech side. A new specialist could be set up in a few years with the right scientific leadership and tens of millions of capital. The barrier is reputation and the reference customer list, not technology per se. The structural shift weighing on the CRO segment in 2025-2026 is not a new entrant but a demand-side shock: smaller US biotech customers, many of whom were the source of incremental Gubra revenue, lost easy access to capital and are running fewer studies.

6. Industry

The demand environment for Gubra's products is dominated by one single fact: obesity is the largest commercial opportunity in pharmaceutical history, and the world's biggest drug companies are all trying to get a share of it. Eli Lilly's Mounjaro/Zepbound franchise generated approximately $39.5bn in the first nine months of 2025 alone (per the J.P. Morgan obesity drugs outlook), surpassing Keytruda as the world's best-selling medicine. Novo Nordisk's semaglutide franchise (Ozempic, Wegovy, Rybelsus) had roughly 49% market share by drug type in 2024. The GLP-1 drug market is projected by Towards Healthcare to reach approximately $132.8bn by 2035, and the obesity-specific GLP-1 segment alone is projected by Precedence Research to grow from approximately $10.1bn in 2026 to approximately $66.6bn by 2035 (23.3% CAGR).

What drives that demand: GLP-1s have shown that pharmacological weight loss is real, durable and large enough to affect mortality, comorbidity rates, and consumer behaviour. The medical, social and commercial implications are enormous, which is why every major pharma without a foothold has been scrambling to build one. AbbVie, the third-largest US pharma by revenue, had no obesity asset until it bought into ABBV-295 in March 2025. Roche, Merck, Sanofi and Pfizer have all made deals or acquisitions to get exposure. This is the demand backdrop that made the AbbVie-Gubra deal possible at $2.2bn in headline value.

Within obesity, two specific sub-trends are most relevant to Gubra. First, the next wave of differentiation is moving beyond GLP-1 to combination products and to drugs with different mechanisms: amylin (where Gubra is leading), GLP-1/amylin combinations (Novo Nordisk's CagriSema, which delivered 20.4% mean weight loss in the Redefine 1 trial), oral formulations (Novo's amycretin, Lilly's orforglipron, Viking's VK2735 oral), triple agonists (Lilly's retatrutide, Gubra-Boehringer's triple), and muscle-sparing assets (Gubra's UCN2 is one of very few clinical-stage assets here). Second, regulators and clinicians are increasingly concerned about body composition: how much of the weight lost is fat vs lean tissue. The April 2026 PMC paper "Muscle Loss in Obesity Therapy" makes the case that this is the new endpoint regulators will examine. That trend directly benefits assets like UCN2.

Where Gubra sits in the global supply chain: it is at the discovery end, three to five years upstream of approved product. It is a discovery and preclinical R&D node, not a manufacturer, not a marketer. Its customers are pharma companies that have downstream development, manufacturing and commercialisation capability.

Regulatory: obesity drugs are regulated under standard FDA and EMA frameworks. Increasingly, regulators are asking for cardiovascular outcomes data (semaglutide's SELECT trial set the new bar), which adds development cost and time. Gubra's exposure to regulation is indirect: it shapes what its partners ultimately need to prove for any Gubra-discovered asset to reach market. The CRO segment is governed by good laboratory practice (GLP) rules for studies that will be part of regulatory submissions.

Cyclicality: pharma R&D budgets are remarkably stable across the cycle for big pharma but highly cyclical for small/mid-cap biotech. The current 2025-2026 weakness in Gubra's CRO segment is a direct downstream effect of the small-biotech funding winter that followed the 2021-2022 peak. As that segment recovers, CRO demand should follow.

Industry tailwinds: huge and durable demand for obesity drugs; pharma BD desperation for differentiated assets; regulatory recognition of body composition as an endpoint; pricing pressure on GLP-1s creating room for newer mechanisms to enter at premium price points. Industry headwinds: the cost of running registrational obesity trials is rising (large sample sizes, long durations, CVOT requirements); the failure mode for any individual obesity asset remains attrition in mid-stage trials due to tolerability or efficacy below the GLP-1 benchmark; and the GLP-1 incumbents are not standing still.

7. Growth Triggers

All triggers below come directly from Gubra's four most recent earnings or trading-statement calls: Q1 2026 (12 May 2026), FY 2025 / Annual Report (27 Feb 2026), Q3 2025 trading statement (7 Nov 2025), and H1 2025 (21 Aug 2025).

• ABBV-295 Phase 2 initiation in Q3 2026. Triggers a milestone payment to Gubra from AbbVie under the $2.2bn licence terms. Confirmed at Q1 2026 call (12 May 2026); previously flagged at FY 2025 call (27 Feb 2026).

  "AbbVie will proceed with the 295 phase II in Q3 2026." (Q1 2026 call, 12 May 2026)

• Boehringer Ingelheim triple agonist into Phase 2 by mid-2026. Triggers a separate Boehringer milestone payment. Confirmed at Q1 2026 call (12 May 2026).

  "Boehringer Ingelheim announced that the triple agonist will move into phase II by middle of the year." (Q1 2026 call, 12 May 2026)

• GUB-UCN2 first-in-human dosing in 2026 H1. Wholly-owned asset; first clinical data will be a major share-price catalyst and a credibility test for the muscle-sparing thesis. Trial design is unusually ambitious (188 participants, up to 16 weeks dosing, both standalone and in combination with incretins). Repeated across H1 2025 (21 Aug 2025), Q3 2025 (7 Nov 2025), FY 2025 (27 Feb 2026), and Q1 2026 (12 May 2026).

• Two Gubra-discovered assets in Phase 2 simultaneously by end-2026. From the Q1 2026 call (12 May 2026):

  "We will have two Gubra-discovered assets in phase II this year and also starting the phase I trial for UCN2." (Q1 2026 call, 12 May 2026)

• CRO segment recovery in H2 2026. Management remains cautiously optimistic about a gradual US biotech funding recovery driving CRO bookings back up. Articulated as guidance at Q1 2026 (12 May 2026); same theme appeared at FY 2025 (27 Feb 2026) and Q3 2025 (7 Nov 2025).

• US CRO sales-team expansion (~20% headcount). Announced at Q1 2026 call (12 May 2026) as a direct response to the US weakness. Designed to capture share as US biotech demand recovers.

• Gubra Ventures first venture creation in H2 2026. New segment, new optionality. Confirmed at Q1 2026 call (12 May 2026); first articulated at FY 2025 call (27 Feb 2026).

  "Gubra Ventures launched to explore externally sourced assets with structured capital allocation. Expected first venture creation in H2 2026." (Q1 2026 call, 12 May 2026; paraphrasing Zoë Johnson)

• Continued pipeline replenishment via new big pharma deals. Management has not pre-announced a specific deal but consistently signals (across all four calls) that the deal flow that produced AbbVie is ongoing and the BD environment for obesity assets remains hot.

• Expanded CRO service lines, including women's health. Mentioned at Q3 2025 (7 Nov 2025). Adds incremental TAM beyond pure metabolic disease.

8. Key Risks

Concentration on ABBV-295 and Boehringer triple as the headline value drivers. A clinical setback at either asset in Phase 2 would not just hit the partner; it would impair Gubra's ability to receive milestones and royalties on what is currently the bulk of its expected long-term cash flow from the biotech segment. Phase 2 is the most likely place to discover an obesity asset's real weakness (efficacy below GLP-1 benchmarks, off-target effects, dose-limiting tolerability). The Boehringer precedent of discontinuing BI 1820237, a previously-disclosed Gubra-originated asset, shows that partners walk away. Probability moderate, impact severe.

GUB-UCN2 muscle-preservation thesis is preclinical only. Mouse data showing muscle preservation does not always translate to humans. The CRHR2 receptor mechanism is novel for obesity and there are no precedent approved drugs in this class. If the Phase 1/2a fails to show preservation of lean mass in humans, the entire "differentiated next-generation" narrative for the asset deflates, and Gubra is left with a less-distinctive pipeline. Probability moderate-to-high (most novel-mechanism Phase 1 obesity assets fail), impact significant.

CRO segment exposure to small/mid-cap biotech funding cycles. Management has now twice cut CRO guidance during 2025-2026 (first at H1 2025, again at Q1 2026, from 5-15% growth to 0-10%). If the US biotech funding environment does not recover on the expected H2 2026 timeline, CRO revenue stagnation extends and the segment's role as a stable cash-flow base for the discovery work erodes.

"We still experience longer decision cycles and increased competition on standard studies." (Trine Nygaard Hamann, Head of CRO, Q1 2026 call, 12 May 2026)

Management is acknowledging the issue directly, not deflecting, which is a credibility plus, but the duration of the slowdown is genuinely outside their control.

Big pharma competitive in-housing. AbbVie, Roche, Sanofi and others are now well-resourced in obesity and may rely less on external discovery partners over time as they build internal capacity. Today's seller's market for obesity assets may not last as long as the multi-year discovery cycle. If Gubra's next-best asset finishes preclinical in 2028-2029, the BD environment may be considerably colder.

Single-site, single-country operational risk. All of Gubra's discovery and CRO work happens in one Danish facility. Any event at the site (fire, biosecurity incident, key-person departure, regulatory action) creates concentrated operational risk that a more distributed competitor would absorb more easily.

Founder dependence. Niels Vrang and Jacob Jelsing remain the intellectual centre of the company (Vrang on the board, Jelsing co-founder). Many of the trust relationships with pharma BD teams that produce licensing deals are personal. A succession over the next decade is inevitable and the company has begun preparing (new CEO Markus Rohrwild, September 2025; layered scientific leadership additions). Execution risk on that transition is real.

Equity dilution from biotech R&D burn during gap years. Between major deals, the discovery half consumes significant cash. The AbbVie upfront and the special dividend masked this in 2025-2026. In a 2027 or 2028 with no new deal, the discovery cost base remains and operating cash flow tightens. If management chose to issue equity to fund a particularly aggressive UCN2 development plan, it would be dilutive.

Currency exposure. Deals are denominated in USD or EUR; reporting is in DKK. Macro currency moves can swing reported DKK figures without underlying business changes.

9. Walk the Talk

The four calls used for this assessment:

• H1 2025: 21 August 2025, hosted by then-CEO Henrik Blou, CSO Louise S. Dalbøge, CFO Kristian Borbos
• Q3 2025 trading statement: 7 November 2025, hosted by new CEO Markus Rohrwild (his first call), CSO Louise S. Dalbøge, CFO Kristian Borbos
• FY 2025 / Annual Report: 27 February 2026, hosted by CEO Markus Rohrwild, CFO Kristian Borbos, CSO Louise S. Dalbøge, CDMO Thomas Langenickel, Head of Ventures Zoë Johnson, Head of CRO Trine Nygaard Hamann
• Q1 2026: 12 May 2026, same leadership team as Q4 2025

The H1 2025 call is the natural starting point because it follows the AbbVie deal closure and is therefore the first call where management's promises become trackable against a substantive business event.

At H1 2025, outgoing CEO Henrik Blou framed the deal as transformational and committed to returning a large slug of capital to shareholders:

"The first half year has been transformational, in a very positive way." (Henrik Blou, H1 2025 call, 21 Aug 2025)

The promised DKK 1bn special dividend was confirmed at the EGM on 27 June 2025 and paid 1-2 July 2025, exactly as outlined. That is a kept promise. Also at H1 2025, management cut full-year CRO guidance for the first time, from 10-20% growth down to "slightly below 2024," and cut CRO EBIT margin guidance from 25-31% to roughly 20%. That cut was a quietly significant admission that the originally-set CRO trajectory was wrong, not just deferred. The reason given (US biotech customer decision-cycle elongation) was specific and verifiable rather than a hand-wave.

By the Q3 2025 trading statement (7 November 2025), the new CEO Markus Rohrwild was in the seat and reaffirmed the revised CRO trajectory: full-year CRO revenue expected 5-10% below 2024, EBIT margin approximately 20%. That is consistent with what was guided in August, neither walked further down nor pretended to be better. UCN2 preclinical results were described as "fantastic" with the commitment that the asset would enter the clinic "in the first half of 2026". That was a specific date-bounded promise on what was then management's most-watched proprietary asset.

By the FY 2025 / Annual Report call (27 February 2026), management restructured the company into three segments (Biotech / CRO / Ventures), confirmed CRO full-year 2025 outcome at DKK 192.5m (close to the revised guidance band), and reiterated UCN2 entering first-in-human in H1 2026. The CEO articulated guidance for 2026 of 5-15% CRO growth and 20-25% EBIT margin, which was a step up from the revised 2025 ambition and effectively a "we expect recovery" call. That recovery thesis was the first datable forward promise.

By the Q1 2026 call (12 May 2026), management cut the 2026 CRO guidance again, from 5-15% growth down to 0-10%, citing the same US biotech funding-cycle reasons. That is the second downgrade to the CRO guidance in twelve months. On the positive side, GUB-UCN2 clinical trial application was confirmed submitted, ABBV-295 Phase 2 timing confirmed as Q3 2026, and the Boehringer triple agonist Phase 2 confirmed for mid-2026 - all consistent with what had been promised at FY 2025 and earlier.

The picture that emerges is of a management team that has been consistently accurate on the biotech pipeline (every promised milestone has either landed or remains on the originally-given timeline) and consistently overly-optimistic on CRO recovery (two downgrades in 12 months, both blamed on the same external factor). That asymmetry is itself useful information: it suggests that biotech execution is what management actually controls and CRO is what management is bad at forecasting. Capital allocation has been disciplined and shareholder-aligned (the DKK 1bn dividend after AbbVie was an explicit return-the-excess-cash move, not a kingdom-building gesture). The CEO transition was telegraphed and orderly. On balance, this is a management team that delivers on what it controls and forecasts conservatively (for biotech) or with too much optimism (for CRO).

Net: a credible biotech execution team with a recurring CRO forecasting blind spot.

10. Shareholder Friendliness Index

Gubra IPO'd in April 2024 at DKK 110 per share on Nasdaq Copenhagen, so the trackable shareholder-return history is shorter than three full years. In 2024 (the first partial year), no ordinary dividend was paid. In 2025, the company announced an extraordinary cash dividend of DKK 1,000 million, equivalent to DKK 61.2 per share, approved at the Extraordinary General Meeting on 27 June 2025 and paid 1-2 July 2025. This was funded directly out of the AbbVie upfront and represented an explicit return of "surplus" cash beyond what management felt the business needed for its growth plans. The board has not yet declared a 2026 ordinary dividend, consistent with a biotech that uses retained capital for R&D between deals. There is no announced share buyback programme, and based on the disclosed shareholder structure (founders Niels Vrang at 30.8% and Jacob Jelsing at 27.8%, both increasing their stakes through open-market purchases in late 2025 and 2026), the share count has not been materially reduced. Conversely, there is no evidence of significant equity dilution either; the IPO was the major issuance event and the share count appears broadly stable since.

Verdict: Returns Capital - one large, explicit, well-timed special dividend (~DKK 1bn from a windfall licensing event) is a clear pro-shareholder act, distinguishing Gubra from biotechs that hoard or burn windfall cash, even though there is not yet a regular dividend or buyback programme to assess.

11. Insider Activities

Insider data sourced from Nasdaq Copenhagen issuer announcements (PDMR reporting under MAR Art. 19) and aggregated via Simply Wall St; individual transactions cross-checked against the company's news feed.

Recent transactions over the past 12 months:

The buying activity is the most striking insider signal in the file. Both founders are actively buying shares in the open market, the CEO has bought, and a board member also bought - all in a roughly six-month window from November 2025 to May 2026. This is broad-based cluster buying by the people who know the business best, and qualifies as a very bullish signal.

Reading the individual buys:

• Niels Vrang has bought three times across roughly five months, adding more than 31,000 shares for a combined outlay above DKK 13m. Vrang already owns approximately 30.8% of the company; he is buying not to build influence but because he sees value at the prevailing price. He is a co-founder, the former CSO and a current board member - he has informational depth few outsiders can match.
• Jacob Jelsing's purchase of 38,792 shares for around DKK 15m on 10 November 2025 is the single largest disclosed insider buy in the period. Jelsing already holds approximately 27.8%; this is conviction signalling at scale, particularly because it came three days after a trading statement that included a CRO downgrade.
• Markus Rohrwild, the new CEO appointed in September 2025, made his first open-market purchase on 7 November 2025, two months into the job. The size (4,300 shares for DKK 1.6m) is modest but the timing - same day as the Q3 2025 trading statement and immediately after a CRO guidance reset - is meaningful. New CEOs typically do not buy on day-of-results unless they want to be seen aligning with shareholders.
• Monika Lessl's smaller purchase on the same date as the CEO's clusters the buying signal further.

No material insider sells are disclosed in the period. There is no evidence of secondary placements, founder distributions to trusts or charitable gifts that would muddy the signal.

Net assessment: this is one of the clearest cluster-buying patterns observable in a European listed biotech. Two founders, the CEO and an independent director have all bought in the open market within a six-month window, with no offsetting sales. The buys span periods both before and after CRO guidance downgrades, suggesting the insiders are looking past near-term services weakness and weighting the value of the discovery pipeline. Bullish signal.

12. Scenarios

Bull case

The bull case is essentially that the obesity gold rush is still in its first innings and Gubra has the discovery engine to put another two or three assets into pharma BD funnels over the next three years. ABBV-295 reads out positive Phase 2 data in 2027, triggering the next big milestone payment from AbbVie and validating the entire amylin-analog thesis at a time when AbbVie is desperate for late-stage obesity differentiation. The Boehringer triple agonist proves competitive against retatrutide on its weight loss and tolerability profile, triggering its own milestone cascade. GUB-UCN2 Phase 1/2a data, in late 2026 or 2027, shows that the muscle-sparing thesis works in humans, at which point Gubra has on its hands not just a clinical asset but a category-defining mechanism that every GLP-1-using pharma needs to license. A licensing deal for UCN2 would dwarf the AbbVie ABBV-295 transaction because Gubra would retain it later into the value curve. Meanwhile the CRO segment recovers as the US biotech funding cycle turns, and the expanded US sales team captures share. Ventures generates one or two interesting in-licensed assets that turn into the next out-licensing pipeline. Capital is returned again. Niels Vrang and Jacob Jelsing's recent open-market buying turns out to have been brilliantly timed.

Base case

The base case is that the biotech pipeline plays out roughly as management has guided. ABBV-295 starts Phase 2 in Q3 2026 and the Boehringer triple agonist enters Phase 2 by mid-year, each triggering modest milestone payments. UCN2 enters the clinic on schedule and produces enough Phase 1 data through 2027 to keep optionality on a future licensing deal, but the muscle-sparing thesis remains preclinically validated rather than clinically proven. The CRO segment grinds out flat-to-mid-single-digit growth in 2026 as US biotech funding only partially recovers, then returns to 10% growth in 2027 as the cycle improves. Ventures launches its first one or two creations but they are too early to move the needle on group results. Management does not announce a major new pharma licence in 2026, but BD conversations remain active. The share count holds roughly steady. Gubra ends the period as a credible specialist with one approved partner asset in sight (ABBV-295 by ~2030-2032 depending on Phase 2/3 success) and a real flagship clinical asset of its own.

Bear case

The bear case is harder than for most biotechs because the cash position is strong and the partner-paid clinical work means Gubra is not the one writing the development cheques. But there are still specific paths to disappointment. ABBV-295 disappoints in Phase 2 by hitting tolerability problems or showing weight loss below the GLP-1 benchmark; AbbVie walks (as Boehringer walked from BI 1820237), and the milestone stream collapses. The Boehringer triple agonist falls behind Lilly's retatrutide on efficacy and Boehringer rationalises its obesity portfolio. GUB-UCN2 Phase 1/2a shows that the muscle-sparing effect was a rodent artefact, and the proprietary asset is no longer differentiated. The US biotech funding cycle stays cold longer than expected; the CRO segment is downgraded again; the 10% long-term growth ambition starts to look aspirational. Meanwhile big pharma in-houses its obesity discovery further, and the BD environment in 2028 is cooler than today. Cash is still ample because of the AbbVie windfall, but the discovery pipeline replenishment stalls and the long-term story compresses to "specialist CRO with one declining royalty stream". The cluster of founder buying in late 2025 / early 2026 looks like it captured the cycle high.

Sources:

Earnings calls and company filings:

• Earnings call transcript: Gubra Q1 2026 results show mixed performance (Investing.com)
• Earnings call transcript: Gubra Q3 2025 sees stock rise on strategic growth (Investing.com)
• Interim Report H1 2025: Group Revenue and Earnings Record-High (Yahoo Finance)
• Annual Report 2025: A record year (Gubra)
• Gubra FY 2025 slides: $2.2bn AbbVie deal drives record results (Investing.com)
• Gubra H1 2025 slides (Investing.com)
• Annual Report 2025 (TradingView mirror)

Company / Partnership announcements:

• Markus Rohrwild appointed new CEO of Gubra (12 Aug 2025)
• AbbVie and Gubra Announce License Agreement (3 Mar 2025)
• Boehringer advances Gubra-originated triple agonist into Phase 2 (Gubra)
• Gubra unveils UCN2 as novel anti-obesity drug candidate (Gubra)
• Gubra submits CTA for GUB-UCN2 (TradingView)
• Extraordinary General Meeting on DKK 1bn dividend (Nasdaq)
• Boehringer-Gubra €250m backloaded obesity deal (Fierce Biotech)
• Bayer-Gubra $253m biobucks heart/kidney deal (Fierce Biotech)
• Camurus and Gubra PTH analog collaboration

Insider transactions:

• Gubra A/S Insider Trading & Ownership Structure (Simply Wall St)
• Reporting of PDMR transactions in Gubra A/S shares - 7 Nov 2025 (PharmiWeb)

Industry context:

• Outlook for Obesity in 2026 (IQVIA)
• How Supply and Demand for Weight Loss Drugs is Playing Out in 2026 (J.P. Morgan)
• Obesity GLP-1 Market Size (Precedence Research)
• Can amylin weight-loss drugs compete in a world of GLP-1s? (C&EN)
• Obesity Space Abuzz With Oral, Amylin Assets (BioSpace)

Background / Competitor research:

• Charles River cardiovascular/metabolic disease models
• Charles River + Crown Bioscience ZDSD rodent model (Fierce Biotech)
• Gubra preclinical CRO obesity research page
• Muscle Loss in Obesity Therapy paper (NCBI PMC)

Report delivered. Q1 2026 (12 May 2026) was used as the most recent reporting period; the four concalls span H1 2025, Q3 2025, FY 2025 and Q1 2026. Section 13 (SemiAnalysis/Stratechery/MBI) omitted - no qualifying coverage exists. Insider activity is the cleanest signal in the file: founders and CEO buying clusters between Nov 2025 and May 2026.